<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03155503</url>
  </required_header>
  <id_info>
    <org_study_id>CTP1S1911A4B2</org_study_id>
    <nct_id>NCT03155503</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects</brief_title>
  <acronym>SUVN-911</acronym>
  <official_title>A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-911 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suven Life Sciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suven Life Sciences Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical
      study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of
      SUVN-911 or placebo will be orally administered to healthy male subjects to evaluate the
      safety, tolerability, and pharmacokinetic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single and multiple ascending dose study to assess the safety, tolerability and
      pharmacokinetics of SUVN-911 administered orally once a day to healthy male subjects. The
      study will be conducted under double-blind conditions.

      The primary objectives are to evaluate the safety and tolerability of SUVN-911 following oral
      administration of single or multiple ascending doses and estimate the maximum tolerated dose
      of SUVN-911, if possible.

      The secondary objectives are to evaluate the single and repeat dose plasma and urine
      pharmacokinetics of SUVN-911 following oral administration of single and multiple ascending
      doses in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Actual">March 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>subjects randomized to drug or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ECG (Electrocardiogram)</measure>
    <time_frame>Range of Day 1-17</time_frame>
    <description>electrocardiogram outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Range of Day 1-17</time_frame>
    <description>blood pressure determination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-SSRS (Columbia Suicidal Severity Rating Scale)</measure>
    <time_frame>Range of Day 1-17</time_frame>
    <description>Columbia Suicidal Severity Rating in multiple doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Maximum concentration observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Determination of maximum time taken to reach the maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (tÂ½)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Elimination rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Single ascending dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of SUVN-911 or placebo in healthy male subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple doses of SUVN-911 or placebo in healthy male subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUVN-911</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Single ascending dose</arm_group_label>
    <arm_group_label>Multiple ascending dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Single ascending dose</arm_group_label>
    <arm_group_label>Multiple ascending dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male aged 18 to 45 years with a body mass index (BMI) between 18 and 30 kg/m2,
             (inclusive).

        Exclusion Criteria:

          -  Standard exclusion criterion for Phase 1 clinical trial in healthy subjects:

               -  History of any clinically significant disease or disorder which, in the opinion
                  of the Investigator, may either put the volunteer at risk because of
                  participation in the study, or influence the results or the volunteer's ability
                  to participate.

               -  History or presence of gastro intestinal (GI), hepatic, or renal disease or any
                  other condition known to interfere with absorption, distribution, metabolism, or
                  excretion of drugs as judged by Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Lomeli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QuintilesIMS Phase 1 Services, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUVN-911</keyword>
  <keyword>Depression</keyword>
  <keyword>single dose</keyword>
  <keyword>multiple dose</keyword>
  <keyword>alpha4 beta2 receptor</keyword>
  <keyword>first in human</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

